

# **VINYL CHLORIDE**

**Geary Olsen**

**October 30, 1989**

## **OUTLINE OF DISCUSSION**

### **I. VINYL CHLORIDE**

- A. Introduction**
- B. Known Cases Worldwide of ASL Associated with VCM**
- C. CMA/EHA Study**
- D. Dow Study**
- E. The Sir Richard Doll Review**
- F. Calculation of Risk**
- G. Various Authors' Conclusions**
- H. Miscarriages and Birth Defects**
- I. Neuropathy**

### **II. THE ST. GABRIEL MISCARRIAGE STUDY**

## **OPRAH WINFREY SHOW**

**JUNE, 1989**


### **Quote from local audience member**

**"The chemical that they make more of here than anywhere else in the country is vinyl chloride and it causes that in the wives, it causes cancer and it causes rare liver disease and it is proven and they make it intentionally and it is immoral and criminal to produce a chemical that is known to kill."**

## **CHRONOLOGY OF PVC PRODUCTION AND HEALTH RISKS**

|               |                                                       |
|---------------|-------------------------------------------------------|
| <b>1942</b>   | <b>Start of commercial PVC production in U.S.</b>     |
| <b>1949</b>   | <b>Earliest references to AOL and hepatic effects</b> |
| <b>1966-7</b> | <b>Detailed description of AOL</b>                    |
| <b>1960's</b> | <b>Reports of hepatomegaly</b>                        |
| <b>1971</b>   | <b>First report of experimental carcinogenicity</b>   |
| <b>1972-3</b> | <b>Detailed description of hepatotoxicity</b>         |
| <b>1974</b>   | <b>First cluster of HAS</b>                           |

# LIVER LOBULE (PANORAMIC VIEW)







FIG. 25-7. Drawing (at high-power magnification) to show how blood from the portal vein and the hepatic artery (*left*) flows into sinusoids, lined by reticuloendothelium, that lie between liver cords, and empties into the central vein (*right*). The way that bile travels in the opposite direction in canaliculi to empty into bile ducts in portal areas is also shown.



R&S 040402

is the standard for vinyl chloride, with a time-weighted average for all exposures not to exceed 50 ppm (Fig 64-1).

### Aero-osteolysis

Aero-osteolysis consists of localized areas of bone necrosis and absorption. These lesions are nontender and are not associated with a periosteal reaction. The hands and fingers are most commonly involved. In a majority of cases, aero-osteolysis is associated with Raynaud's phenomenon and sclerodermatous skin changes.




FIG 64-1.

A worker entering a PVC reactor vessel to clean out caked polymer adhering to the inner surfaces. During the polymerization reaction, sludge from the slurry has a tendency to form a crust on the impeller mechanism as well as the tank inner surfaces. The caked polymer is periodically hand-chipped by workers inside the tank, and this is the operation that subjected workers to the highest concentrations of vinyl chloride. Current practice requires that flexible ducts be used for purging with clean air before the worker enters. In addition, workers in this operation must be provided with positive-pressure air-supplied respirators, preferably the hood type. Demand-type respirators have been used, but may not offer the same protection as the continuous-flow type of hood respirator. (Courtesy of Maurice N. Johnson, M.D., B.F. Goodrich Company, Akron, Ohio. Photographer—H. Groskinski.)

in two workers.

Of the 533 PVC workers in this plant, two cases were identified: hands of these workers. The terminal phalanges of the feet of these workers, also autoclave cleaners, demonstrated Raynaud's phenomenon.

Wilson<sup>22</sup> studied 31 cases of occupational disease of the hands of workers engaged in vinyl chloride processes. Most of these workers had worked with walls and other equipment in the polymerization process. Aero-osteolysis was localized to the distal phalanges and was associated with Raynaud's phenomenon. The disorder resulted from a combination of physical insult, and personal idiosyncrasy, and were genetic causes. Prevalence was reported to be among employees performing similar work, and among workmen processing the polymer or manufacturing it. More than 100 workers handled the material processed it into plastic products did not develop aero-osteolysis.

In 1970 and 1971, Dinman<sup>23</sup> of the Institute of Industrial Health at The University of Michigan conducted a comprehensive study of aero-osteolysis in vinyl chloride compounding and PVC. The epidemic represented more than 5,000 workers in 32 plants were discovered, of which 25 had a definite diagnosis of aero-osteolysis and 16 suspicious diagnoses of aero-osteolysis and hand cleaning of the polymerizers.

Dodson<sup>24</sup> determined that work practice was the specific agent or combination of agents, appropriate occurrence of the disease. He thought the disease was localized in nature, but was multifactorial, suggesting a combination of agent or portal of entry, suggesting sensitization of susceptibility. An industrial hygiene epidemiologic investigation revealed vinyl chloride in the reactor before ventilating to be about 50 ppm. During the operation of the containers, the vinyl chloride concentration in the reactor during scraping was found to be usually around 50 ppm. It was found that scraping polymerized vinyl chloride so that levels of 60 ppm were found close to the hands during these operations, potentially high worker respiratory inhalation. Constituents of the scrapings of the reactor vessel included polymerized resins, unreacted catalysts, and the polymerized vinyl chloride. No serious disease was reported in any of the above-mentioned cases. Some workers had been partially disabled because of hand soreness and restriction in manual activity. With proper protection and careful hygienic measures, all these cases can be prevented (Fig 64-2).

Veltman et al.<sup>25</sup> reported findings in 70 workers who used autoclaves and centrifuges, during drying and sin-

R&S 040403



R&S 040404

**FIG 64-2.**

The solid, caked polymer must be removed by chisels, hammers, and handpicks. Neither workers nor management may be aware of the hazard involved when a spark is generated by steel on steel. It is not uncommon to open a pocket of the cake lining the vessel. The pocket may contain liquid vinyl chloride monomer. It is very possible that the lower explosive limit for vinyl chloride monomer (33,000 ppm) can be reached during the chipping with steel on steel. Reactor vessels have exploded, leaving nothing but a crater in the ground where the plant once stood. Reactor chipping or cleaning tools should be of the nonsparking type. To minimize worker entry, some companies use high-pressure water guns to remove the caked polymer. These water guns may operate from 9,000 to 13,000 pounds of pressure per square inch. This in itself may produce a serious safety hazard. Some attempts in the United States to remove the caked slurry have utilized closed solvent cleaning systems in which solvents such as tetrahydrofuran are used. To date, such solvent cleaning systems have been relatively unsuccessful. Recently completed production systems using 30,000-gallon reactor vessels have been utilizing automatic high-pressure water cleaning guns and solvent systems to minimize or eliminate the need for worker entry into reactor vessels. Older reactor vessels, which contain cooling vanes of heat exchangers, complicate the cleaning process and high-pressure water guns and solvent systems cannot be used in these tanks. (Courtesy of Maurice N. Johnson, M.D., B. F. Goodrich Company, Akron, Ohio. Photographer—H. Groskinski.)

people in a group of 26<sup>2</sup> workers in a vinyl chloride polymerization plant. Signs of abnormal peripheral circulation were much more frequently in those workers with definite disease. Findings included numbness to cold, pain, cyanosis, involvement of the fingers, and Raynaud's syndrome. An abnormal Allen test, pseudoclubbing in 8.75%, changes in 6.4%.

The specific effect of VCM culminates in neural, dermal, and circulatory changes. It has been in doubt. The superficial resclerosis (scleroderma) has prompted a report of 22 PVC workers by Ward et al.<sup>25</sup> in 1976. 6 workers had prodromal signs, 10 had typical Raynaud's syndrome, and 6 had scleroderma-like changes in the joints of the distal phalanges and fingers. The Raynaud's syndrome was described as symmetrical numbness in the fingers with increased digital arteries. Cryoglobulinemia (22.7%) were plasma proteins. Those with no signs of disease were more likely to have immunologic changes. In 5 of 22 and IgM in 1 of 22. In 10 of 22 and IgG in 6 of 22. In 10 of 22 and IgG in 6 of 22. In 10 of 22 and IgG in 6 of 22.

Cryoglobulins were also seen in 10 of 22 workers with vinyl chloride disease. These workers were patients with vinyl chloride disease. Findings encompassing abnormal blood, nervous system, lungs, and possible VCD; and 35 vinyl chloride workers were seen in 66%, 44% found in 55%, 27%, and 0%, Tl IgG, C3, and fibrinogen. Rheumatoid patients when measured by the latex agglutination test were positive in low titer by hemagglutination test. Definite VCD and 22.7% of those with definite VCD showed the presence of immune complexes during cold exposure. Within the lumen of small blood vessels, these authors found VCM binds to IgG-producing antigen-antibody immune complexes during cold exposure and stimulate complement activation and the conversion of fibrinogen to fibrin and small blood vessels.

## Liver

A hepatitis-like effect has been reported. In a study of 70 workers in a vinyl chloride polymerization plant, 10 workers had signs of abnormal peripheral circulation.

## CAUSES OF ASL

- VCM
- Inorganic arsenic
- Thorotrast
- Androgenic - anabolic steroids

## **TOXICOLOGY**

- 1. HAS is linked to the amount of VCM metabolized rather than to VCM concentration.**
- 2. Reactive intermediates, particularly the epoxide (chloroethylene oxide) found by oxidative metabolism of carbon/carbon double bond, are most likely the carcinogenic agents.**
- 3. Short-lived metabolites are formed in the hepatocyte but are carcinogenic in the adjacent cells to which they migrate presumably because their cells have less detoxification potential.**
- 4. Reactive metabolites covalently bond to macromolecules such as DNA.**

## **VCM-INDUCED VS. CLASSIC HEPATOTOXICITY**

### **VCM-induced hepatotoxicity:**

**relatively silent progression  
not detected early by standard liver function tests  
effective screening tests lacking  
least common of all causes of hepatotoxicity  
various parts of spectrum seen with VCM, Thorotrast,  
arsenic, and steroids (androgenic-anabolic)**

### **Classic hepatotoxicity:**

**clinical signs and symptoms appear early  
hepatic effects noted by enzyme changes, and other readily  
available laboratory tests  
many clinical screening tests are used  
wide array of hepatotoxins have been identified**

**RETROSPECTIVE ESTIMATES OF TYPICAL  
TWA 8-HOUR PERSONAL EXPOSURES****Estimate****Year****1000****1945-1955****400-500****1955-1960****300-400****1960-1970****150****Mid 1973****5****1975**

## **VINYL CHLORIDE ILLNESS**

- 1. Enlargement of liver and spleen with a specific histologic appearance.**
- 2. Patchy infiltration of the skin resembling scleroderma.**
- 3. Many changes in the tips of the fingers described as acroosteolysis.**
- 4. Peripheral circulatory changes identical with the classical picture of Raynaud's syndrome.**

**ASSOCIATION OF PLASTICS MANUFACTURERS  
IN EUROPE WORLDWIDE REGISTRY OF ASL  
RESULTING FROM EXPOSURE TO VCM**

- Begun in 1974
  - Cases must be histologically confirmed
- Mean age at diagnoses = 52 years
- Incidence of ASL reaches a peak of 20-29 years after exposure
- 43% of affected individuals were autoclave cleaners

**NUMBERS OF VINYL CHLORIDE RELATED  
CASES OF ANGIOSARCOMA OF THE LIVER  
BY DATE OF DEATH**

| Period  | Number of Deaths |
|---------|------------------|
| 1955-59 | 2                |
| 1960-64 | 4                |
| 1965-69 | 9                |
| 1970-74 | 23               |
| 1975-79 | 46               |
| 1980-84 | 34               |
| Total   | 118              |

## ASL REGISTRY UPDATE - THROUGH 1987

### Cases

|      |   |
|------|---|
| 1985 | 5 |
| 1986 | 3 |
| 1987 | 4 |

Of 50 cases in North America, 42 have occurred at 4 factories.

Louisville (15)  
Shawinigan (12)  
S. Charleston (10)  
Niagara Falls (5)

**DISTRIBUTION OF CASES BY COUNTRY**

| <b>Country</b> | <b>Number<br/>of<br/>Cases</b> | <b>Number of<br/>Factories<br/>Reporting Cases</b> |
|----------------|--------------------------------|----------------------------------------------------|
| United States  | 35                             | 10                                                 |
| West Germany   | 26                             | 6                                                  |
| France         | 18                             | 5                                                  |
| Canada         | 10                             | 1                                                  |
| United Kingdom | 9                              | 2                                                  |
| Sweden         | 5                              | 1                                                  |
| Italy          | 4                              | 4                                                  |
| Yugoslavia     | 4                              | 1                                                  |
| Czechoslovakia | 2                              | 1                                                  |
| Japan          | 2                              | 1                                                  |
| Belgium        | 2                              | 1                                                  |
| Norway         | 1                              | 1                                                  |
| Total          | 118                            | 34                                                 |

## **EHA UPDATE COHORT DEFINITION**

- **9,370 men who had worked at least one year in jobs involving exposure to vinyl chloride prior to January 1, 1973.**
- **32 U.S. plants**
- **Observed through December 31, 1982**

**EHA STUDY**  
**OBSERVED AND EXPECTED DEATHS BY**  
**CAUSE, SMRS AND 95% CONFIDENCE LIMITS**

| Cause                              | OBS  | EXP    | SMR | 95% CL  |
|------------------------------------|------|--------|-----|---------|
| All Causes                         | 1536 | 1705.3 | 90  | 86-95   |
| All Cancers                        | 359  | 341.7  | 105 | 94-117  |
| Liver and Biliary Tract*           | 37   | 5.8    | 641 | 450-884 |
| Lung                               | 111  | 115.9  | 96  | 76-116  |
| Brain and CNS                      | 23   | 12.8   | 180 | 114-271 |
| Lymphatic and Hematopoietic System | 37   | 36.3   | 102 | 72-141  |
| Nonmalignant Respiratory Disease   | 70   | 87.6   | 80  | 62-101  |
| Emphysema, including COPD          | 41   | 22.8   | 180 | 129-244 |

\*7 Biliary tract cancers versus 2.7 expected (SMR = 256; 95% CL = 245-511).

# EHA STUDY

## SUMMARY OF CANCER OF LIVER AND BILIARY TRACT

### Duration of Exposure

| <u>&lt;10 Years</u> |            | <u>10-19.9 Years</u> |            | <u>20+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 6                   | 182        | 20                   | 1235*      | 11               | 1284*      |

### Years Since First Exposure

| <u>&lt;20 Years</u> |            | <u>20-29.9 Years</u> |            | <u>30+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 10                  | 386*       | 11                   | 590*       | 16               | 1218*      |

### Year of First Exposure

| <u>&lt;1950</u> |            | <u>1950-1959</u> |            | <u>1960+</u> |            |
|-----------------|------------|------------------|------------|--------------|------------|
| <u>OBS</u>      | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> | <u>OBS</u>   | <u>SMR</u> |
| 27              | 780*       | 7                | 440*       | 3            | 419        |

### Type of Plant

| <u>VCM</u> |            | <u>PVC</u> |            |
|------------|------------|------------|------------|
| <u>OBS</u> | <u>SMR</u> | <u>OBS</u> | <u>SMR</u> |
| 1          | 326        | 31         | 693*       |

# EHA STUDY

## SUMMARY OF ALL CANCER EXCLUDING LIVER AND BILIARY TRACT

### Duration of Exposure

| <u>&lt;10 Years</u> |            | <u>10-19.9 Years</u> |            | <u>20+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 174                 | 92         | 94                   | 102        | 54               | 100        |

### Years Since First Exposure

| <u>&lt;20 Years</u> |            | <u>20-29.9 Years</u> |            | <u>30+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 120                 | 87         | 122                  | 105        | 80               | 96         |

### Year of First Exposure

| <u>&lt;1950</u> |            | <u>1950-1959</u> |            | <u>1960+</u> |            |
|-----------------|------------|------------------|------------|--------------|------------|
| <u>OBS</u>      | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> | <u>OBS</u>   | <u>SMR</u> |
| 166             | 93         | 107              | 105        | 49           | 90         |

### Type of Plant

| <u>VCM</u> |            | <u>PVC</u> |            |
|------------|------------|------------|------------|
| <u>OBS</u> | <u>SMR</u> | <u>OBS</u> | <u>SMR</u> |
| 23         | 110        | 241        | 94         |

# EHA STUDY

## SUMMARY OF CANCER OF THE LUNG

### Duration of Exposure

| <u>&lt;10 Years</u>   | <u>10-19.9 Years</u>  | <u>20+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 59 93                 | 37 114                | 15 75                 |

### Years Since First Exposure

| <u>&lt;20 Years</u>   | <u>20-29.9 Years</u>  | <u>30+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 44 104                | 45 105                | 22 72                 |

### Year of First Exposure

| <u>&lt;1950</u>       | <u>1950-1959</u>      | <u>1960+</u>          |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 54 90                 | 39 106                | 18 96                 |

### Type of Plant

| <u>VCM</u>            | <u>PVC</u>            |
|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 1 -                   | 29 -                  |

# EHS STUDY

## SUMMARY OF CANCER OF BRAIN AND CNS

### Duration of Exposure

| <u>&lt;10 Years</u>   | <u>10-19.9 Years</u>  | <u>20+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 13 165                | 4 121                 | 6 386                 |

### Years Since First Exposure

| <u>&lt;20 Years</u>   | <u>20-29.9 Years</u>  | <u>30+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 13 184                | 6 158                 | 4 210                 |

### Year of First Exposure

| <u>&lt;1950</u>       | <u>1950-1959</u>      | <u>1960+</u>          |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 9 156                 | 7 164                 | 7 256                 |

### Type of Plant

| <u>VCM</u>            | <u>PVC</u>            |
|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 2 220                 | 16 169                |

# EHA STUDY SUMMARY OF LYMPHATIC AND HEMATOPOIETIC CANCER

## Duration of Exposure

| <u>&lt;10 Years</u>   | <u>10-19.9 Years</u>  | <u>20+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 20 91                 | 12 128                | 5 104                 |

## Years Since First Exposure

| <u>&lt;20 Years</u>   | <u>20-29.9 Years</u>  | <u>30+ Years</u>      |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 16 88                 | 14 130                | 7 97                  |

## Type of Plant

| <u>VCM</u>            | <u>PVC</u>            |
|-----------------------|-----------------------|
| <u>OBS</u> <u>EXP</u> | <u>OBS</u> <u>EXP</u> |
| 0 -                   | 31 114                |

## Year of First Exposure

| <u>&lt;1950</u>       | <u>1950-1959</u>      | <u>1960+</u>          |
|-----------------------|-----------------------|-----------------------|
| <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> | <u>OBS</u> <u>SMR</u> |
| 19 107                | 13 114                | 5 71                  |

# EHA STUDY

## SUMMARY OF EMPHYSEMA MORTALITY

### Duration of Exposure

| <u>&lt;10 Years</u> |            | <u>10-19.9 Years</u> |            | <u>20+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 25                  | 209*       | 11                   | 167        | 5                | 117        |

### Years Since First Exposure

| <u>&lt;20 Years</u> |            | <u>20-29.9 Years</u> |            | <u>30+ Years</u> |            |
|---------------------|------------|----------------------|------------|------------------|------------|
| <u>OBS</u>          | <u>SMR</u> | <u>OBS</u>           | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> |
| 11                  | 158*       | 17                   | 198*       | 13               | 179        |

### Year of First Exposure

| <u>&lt;1950</u> |            | <u>1950-1959</u> |            | <u>1960+</u> |            |
|-----------------|------------|------------------|------------|--------------|------------|
| <u>OBS</u>      | <u>SMR</u> | <u>OBS</u>       | <u>SMR</u> | <u>OBS</u>   | <u>SMR</u> |
| 24              | 174*       | 12               | 189        | 5            | 187        |

### Type of Plant

| <u>VCM</u> |            | <u>PVC</u> |            |
|------------|------------|------------|------------|
| <u>OBS</u> | <u>SMR</u> | <u>OBS</u> | <u>SMR</u> |
| 1          | 83         | 29         | 163        |

# **DOW CHEMICAL VINYL CHLORIDE MORTALITY STUDY**

## **Michigan Division**

- **593 employees who were potentially exposed to vinyl chloride monomer**
- **1942-1982**
- **17,114 person-years**
- **28.9 person-years average per person**

**OBSERVED AND EXPECTED DEATHS FOR SELECTED  
CAUSES EXCLUDING EMPLOYEES WITH PRIOR  
EXPOSURE TO ARSENIC INSECTICIDES, 1942-1982**

| <b>Cause of Death<br/>(ICD-8)</b>               | <b>Obs</b> | <b>Exp</b> | <b>SMR†</b> | <b>95% CI⊕</b> |
|-------------------------------------------------|------------|------------|-------------|----------------|
| All causes                                      | 130        | 151.9      | 86          | 72-102         |
| All cancers (140-209)                           | 27         | 31.7       | 85          | 56-124         |
| Digestive system cancer (150-159)               | 9          | 8.5        | 106         | 48-201         |
| Liver cancer (155, 156)                         | 1          | 0.6        | - §         | 4-899          |
| Respiratory system cancer (160-163)             | 10         | 11.3       | 89          | 42-163         |
| Brain cancer (191, 192)                         | 2          | 1.1        | - §         | 23-682         |
| All circulatory diseases (390-458)              | 65         | 75.4       | 86          | 67-110         |
| All nonmalignant respiratory diseases (460-519) | 9          | 8.6        | 104         | 48-198         |
| All accidents (E800-E949)                       | 8          | 10.9       | 74          | 32-144         |

\* Expected numbers are based on calendar time and age-specific mortality rates of U.S. white men.

† Standardized mortality ratio; observed divided by expected number of deaths X 100.

⊕CI, confidence interval of Obs/Exp.

§ Not calculated when expected number of deaths fewer than 5.

Liver cancer was an Intrahepatic bile duct carcinoma.

## **DOSE-RESPONSE RELATIONSHIP**

- Undetermined
- Less than 25 ppm
- 25-200 ppm TWA
- 200+ ppm TWA
- Based on highest rated job assignment for at least 1 month

**Men with at least 5 years of exposure above 200 ppm  
(7 observed versus 2.8 expected). No predominant  
tumor site or unique histologic type.**

R&S 040425

**A**

**VCM REVIEW BY**  
**SIR RICHARD DOLL**

**1988**

**OBSERVED AND EXPECTED NUMBER OF DEATHS FROM DIFFERENT  
CANCERS REPORTS IN THE FOUR PRINCIPAL STUDIES**  
(O = OBSERVED NUMBER OF DEATHS, E = NUMBER OF DEATHS)

| Type of Class of Cancer        | <u>United States</u> |        | <u>United Kingdom</u> |        | <u>Canada</u> |       | <u>Italy</u> |      |
|--------------------------------|----------------------|--------|-----------------------|--------|---------------|-------|--------------|------|
|                                | O <sup>a</sup>       | E      | O                     | E      | O             | E     | O            | E    |
| Buccal cavity and pharynx      | 13                   | 11.55  | 4                     | 3.58   | 0             | 0.64  | 1            | 0.8  |
| Stomach                        | 11                   | 16.01  | 26                    | 23.91  | -             | -     | 3            | 3.0  |
| Large intestine                | 21                   | 28.79  | 9                     | 13.94  | -             | -     | 0            | 1.2  |
| Liver                          | -                    | -      | 11                    | 1.94   | 8             | 0.14  | 1            | 0.6  |
| Liver and gallbladder          | 39                   | 5.77   | -                     | -      | -             | -     | -            | -    |
| Pancreas                       | 17                   | 18.40  | 7                     | 9.88   | -             | -     | 0            | 0.7  |
| Lung                           | 118                  | 115.87 | 81                    | 92.12  | 2             | 5.78  | 12           | 6.1  |
| Melanoma                       | -                    | -      | 2                     | 1.74   | -             | -     | 0            | 0.2  |
| Testis                         | -                    | -      | 2                     | 1.38   | }             | 1.33  | -            | -    |
| Bladder                        | 5                    | 8.46   | 14                    | 8.00   |               |       | 1            | 0.7  |
| Kidney                         | 12                   | 9.06   | 3                     | 4.10   |               |       | -            | -    |
| Other and unspecified urinary  | -                    | -      | 3                     | 4.29   |               |       | -            | -    |
| Brain                          | 25                   | 12.76  | 4                     | 6.18   | }             | 0.60  | -            | -    |
| Eye and central nervous system | -                    | -      | -                     | -      |               |       | -            | -    |
| Thyroid                        | -                    | -      | 2                     | 0.43   | }             | 1.67  | -            | -    |
| Lympho- and reticulosarcoma    | 12                   | 7.98   | 4                     | 2.35   |               |       | -            | -    |
| Hodgkin's disease              | 3                    | 5.45   | 3                     | 2.50   |               |       | 0            | 0.4  |
| Leukemia                       | 14                   | 13.94  | 7                     | 5.16   |               |       | 0            | 0.7  |
| Multiple myeloma               | 11                   | 8.37   | 2                     | 2.35   |               |       | -            | -    |
| Other lymphatic                | -                    | -      | -                     | -      |               |       | -            | -    |
| Other                          | 46                   | 40.50  | 18                    | 8.12   | 2             | 0.95  | 9            | 4.5  |
| All cancers                    | 383                  | 341.73 | 235                   | 228.60 | 20            | 16.37 | 30           | 21.1 |

a

Observed deaths multiplied by 1.0674 and rounded off to the nearest integer to allow for deaths without discovered cause.

**NUMBERS OF DEATHS FROM NONMALIGNANT AND ALL CAUSES  
REPORTED IN THE FOUR PRINCIPAL STUDIES  
(O = OBSERVED NUMBER OF DEATHS, E = NUMBER OF DEATHS)**

| Type of Class of Cancer   | <u>United States</u> |         | <u>United Kingdom</u> |     | <u>Canada</u>  |       | <u>Italy</u> |      |
|---------------------------|----------------------|---------|-----------------------|-----|----------------|-------|--------------|------|
|                           | O <sup>a</sup>       | E       | O                     | E   | O              | E     | O            | E    |
| Ischemic heart disease    | 521                  | 597.73  | 276                   | 288 | 25             | 31.67 | 19           | 27.4 |
| Other circulatory disease | 157                  | 123.55  | 105                   | 141 |                |       |              |      |
| Bronchitis <sup>b</sup>   | 44                   | 22.83   | 36                    | 44  |                |       |              |      |
| Pneumonia                 | 16                   | 31.94   | 40                    | 61  | 6              | 3.21  | 3            | 5.0  |
| Other respiratory disease | 15                   | 32.84   |                       |     |                |       |              |      |
| Cirrhosis of the liver    | 37                   | 56.06   | 5                     | 5   | 4 <sup>c</sup> | 3.85  | 4            | 5.2  |
| Other digestive disease   | 27                   | 39.52   | -                     | -   |                |       | 3            | 2.7  |
| Other diseases            | 67                   | 115.68  | 43                    | 76  | 2 <sup>d</sup> | 5.40  | 2            | 7.0  |
| All nonmalignant causes   | 1153                 | 1363.54 | 545                   | 665 | 36             | 54.76 | 36           | 56.4 |
| All causes                | 1536                 | 1705.27 | 894                   | 894 | 59             | 71.07 | 6            | 77.5 |

<sup>a</sup>Observed deaths multiplied by 1.0674 and rounded off to the nearest integer to allow for deaths without discovered cause.

<sup>b</sup>Emphysema in data from the United States.

<sup>c</sup>Includes two cases certified as cirrhosis of the liver which proved to be angiosarcoma of the liver.

<sup>d</sup>Includes one case with cause unknown.

**MORTALITY FROM VARIOUS CANCERS AMONG VINYL CHLORIDE  
WORKERS IN 49 PLANTS IN THE FOUR PRINCIPAL STUDIES  
COMBINED**

(O = OBSERVED NUMBER OF DEATHS, E = NUMBER OF DEATHS,  
SMR = STANDARDIZED MORTALITY RATIO))

| Type or Class of Cancer             | O   | E      | SMR |
|-------------------------------------|-----|--------|-----|
| Mouth and pharynx                   | 18  | 16.57  | 109 |
| Digestive system (other than liver) | 125 | 154.59 | 81  |
| Respiratory system                  | 223 | 229.36 | 97  |
| Lung                                | 211 | 214.09 | 99  |
| Genitourinary system                | 70  | 62.81  | 111 |
| Melanoma                            | 2   | 1.94   | -   |
| Brain                               | 29  | 19.54  | 148 |
| Thyroid                             | 2   | 0.43   | -   |
| Lymphatic and hematopoietic system  | 57  | 50.87  | 112 |
| Other                               | 83  | 63.24  | 131 |
| All other than of the liver         | 609 | 599.35 | 102 |

**MORTALITY FROM LUNG CANCER IN THE SERIES FROM THE  
UNITED STATES (US) AND THE UNITED KINGDOM (UK) BY  
CHARACTERISTICS RELEVANT TO AN OCCUPATIONAL HAZARD**

**(O = OBSERVED NUMBER OF DEATHS, E = NUMBER OF DEATHS,  
SMR = STANDARDIZED MORTALITY RATIO))**

| Data <sup>a</sup><br>Characteristic                                         | <u>Category 1</u> |        |     | <u>Category 2</u> |       |     |
|-----------------------------------------------------------------------------|-------------------|--------|-----|-------------------|-------|-----|
|                                                                             | O <sup>b</sup>    | E      | SMR | O <sup>b</sup>    | E     | SMR |
| Observed 20 years or more<br>after first employment (1),<br>others (2)      | 114               | 113.96 | 100 | 85                | 93.83 | 91  |
| Employed 10 years or more<br>in the US (1), others in the US (2)            | 55                | 52.45  | 105 | 63                | 63.44 | 99  |
| Employed before 1956 in the<br>UK (1), others in the UK (2)                 | 52                | 51.39  | 101 | 29                | 40.50 | 72  |
| Ever employed as autoclave<br>worker in the UK (1), others<br>in the UK (2) | 16                | 17.08  | 94  | 65                | 74.82 | 87  |

<sup>a</sup> The numbers in parentheses designate the category.

<sup>b</sup> Expected numbers are based on calendar time and age-specific mortality rates of U.S. white men.

**MORTALITY FROM CHRONIC OBSTRUCTIVE LUNG DISEASE<sup>a</sup> IN THE  
SERIES FROM THE UNITED STATES AND THE UNITED KINGDOM BY  
CHARACTERISTICS RELEVANT TO AN OCCUPATIONAL HAZARD**

(O = OBSERVED NUMBER OF DEATHS, E = NUMBER OF DEATHS,  
SMR = STANDARDIZED MORTALITY RATIO))

| Data <sup>b</sup><br>Characteristic                                                      | <u>Category 1</u> |       |     | <u>Category 2</u> |       |     |
|------------------------------------------------------------------------------------------|-------------------|-------|-----|-------------------|-------|-----|
|                                                                                          | O                 | E     | SMR | O                 | E     | SMR |
| Observed 20 years or more<br>after first employment (1),<br>others (2)                   | 30                | 15.8  | 190 | 11                | 7.0   | 157 |
| Employed 10 years or more<br>in the US (1), others in the US (2)                         | 16                | 10.9  | 147 | 25                | 12.0  | 208 |
| Employed before 1956 in the<br>UK (1), others in the UK (2)                              | 26                | 30.17 | 86  | 10                | 13.60 | 74  |
| Ever employed as autoclave<br>worker in the UK (1), others<br>in the UK (2) <sup>c</sup> | 3                 | 6.55  | 46  | 33                | 37.22 | 89  |

<sup>a</sup> Described as emphysema in the US study and as bronchitis in the United Kingdom study.

<sup>b</sup> The numbers in parentheses designate the category.

<sup>c</sup> Men ever employed as a bagger or drier, occupations which would have caused the greatest occupational exposure to polyvinyl chloride dust, experienced one death from bronchitis against 4.98 expected.

## **CALCULATION OF RISK**

**Calculations based on the amount of material metabolized on human data have produced exposure values of about 1 ppm for a  $10^{-6}$  lifetime risk.**

## **CALCULATION OF RISK**

**Studies of the quantitative aspect of VCM metabolism have shown that there is a dose dependency in the rate of metabolism.**

**As the dose of VCM increases, the proportion exhaled increases and that excreted in the urine and feces decreases.**

## **CALCULATION OF RISK**

**In rats, VCM has been shown to be metabolized extensively. The highly reactive intermediate in the metabolic process, chloroethylene oxide, reacts with cellular macromolecules, including DNA to produce the actual lesions leading to mutations/induction of cancer.**

## **CALCULATION OF RISK**

**Estimation of the exposure levels likely to cause a lifetime risk of ASL of  $10^{-6}$  on laboratory data may range as low as  $3.9 \times 10^{-7}$  ppb (Multi-hit) or as high as 1400 ppb (log-probit). Reasons for this variability include: 1) rate of VCM conversion is limited at high levels of exposures giving inaccurate estimates of the slope of the dose response-relationships; 2) has not been able to estimate the rate of conversion in man; 3) variability of subsets of experimental data used on mathematical models; 4) various differences in assumptions of mathematical models and 5) assumptions used in applying the models.**

## **CALCULATION OF RISK**

**Although there was considerable variability in the dose-response relationship in the different experiments reported, in all cases a total metabolized dose equivalent to an inhalation of 200 ppm was required to produce an elevation in ASL incidence.**

**HOW MANY MORE ASL CASES ARE  
EXPECTED TO DEVELOP WORLDWIDE  
DUE TO VCM EXPOSURE IN NEXT 30 YEARS?**

|                       | <b>Estimated<br/>New<br/><u>Cases</u></b> |
|-----------------------|-------------------------------------------|
| <b>Forman et al</b>   | <b>200-250</b>                            |
| <b>Purchase et al</b> | <b>150-350</b>                            |
| <b>Nicholson</b>      | <b>1500</b>                               |

**There has not been a reported death of angiosarcoma of the liver for any Dow employee or employee of a Louisiana chemical plant.**

## **VCM**

### **OCCUPATIONAL STUDY CONCLUSIONS**

VCM caused angiosarcoma of the liver in occupations which had high exposures prior to 1974.

#### **Cancer**

Sir Richard Doll (1988), "There is too little evidence to confirm or refute the suggestion that vinyl chloride might cause melanoma or cancers of the thyroid, brain, and lymphatic and hematopoietic systems. None of the small excesses that have been recorded point specifically to an occupational hazard . . . and most are likely to be the sort of chance effect that is certain to be observed when many types of cancers are examined in many different studies.

## **VCM**

### **OCCUPATIONAL STUDY CONCLUSIONS**

**Sir Richard Doll (1988, continued), "The combined data for the mortality from respiratory cancer fail, at first sight, to support the hypothesis regarding lung cancer (SMR 97). Higher ratios for lung cancer have, however, been observed consistently in the subgroups in which the effect of an occupational hazard would be most likely seen (that is, men employed for more than 10 years, exposed to higher than average concentrations, or observed more than 20 years after first exposure). In two of the supplementary studies, it was also noted that the mortality from lung cancer was specifically increased among the most heavily exposed workers."**

## **VINYL CHLORIDE COMMUNITY HEALTH CONCLUSIONS**

**Sir Richard Doll (1988), "A very small risk of angiosarcoma may have occurred as a result of vinyl chloride escaping into the environment around plants handling vinyl chloride in the past, but the evidence indicates that the current risk to the general public (if any) must be negligible."**

## **VCM OCCUPATIONAL STUDY CONCLUSIONS**

**Jones et al (British study, 1988), "This study does not offer any anecdotal or statistical evidence for an association between brain cancer and VCM exposure."**

**Jones et al (1988), "The results of the study do not demonstrate any association between VCM and lung cancer deaths."**

**Wu et al (NIOSH, 1989), "Our data do not support the hypothesis the excess risk of lung cancer and brain cancer which had been observed at this plant is associated with exposure to either VCM or PVC dust. The lack of significant findings in the cohort analyses for these two cancers was further supported by the lack of a dose response in the case-control studies for exposure to either VCM or PVC dust."**

## **VCM OCCUPATIONAL STUDY CONCLUSIONS**

**Purchase et al (1987), "For brain cancer the association between exposure to VCM and an increased incidence was less clear because of the lower relative risk. Neoplasms of the respiratory tract, digestive system, lymphatic and hematopoietic system, buccal cavity and pharynx, cardiovascular system and colon/stomach were reported to show an increased incidence in one or more studies, but to show no increase, or in some cases a decrease, in incidence in other studies."**

## **VCM**

### **OCCUPATIONAL STUDY CONCLUSIONS**

Wong et al (1987), "Contrary to our observation on liver cancer, a higher brain cancer mortality risk was found among those who were exposed after age 35 and who were exposed in or after 1960 than those who were exposed before 1960 and at a younger age. Based on the limited exposure information available in this mortality study, the implication of this difference in risk profile is not clear at this point."

"For the entire cohort, 115 deaths were due to cancer of the respiratory system, compared to 122.25 expected. The corresponding SMR was 94.5. Our study, at the 0.05 significance level, has 80% statistical power to detect an SMR for cancer of the respiratory system as small as 124. Therefore, we can conclude that our study has clearly demonstrated that there is no relationship between occupational exposure to vinyl chloride and cancer of the respiratory system."

## **VCM**

### **OCCUPATIONAL STUDY CONCLUSIONS**

Wong et al (1987), "In our study, 37 deaths were due to lymphatic and hematopoietic cancer, compared to 36.28 expected. The corresponding SMR was 102.0. Our study, at the 0.05 significance level, has 80% power to detect an SMR for lymphatic and hematopoietic cancer as small as 145. Therefore, our study has adequate power to detect an increased risk in lymphatic and hematopoietic cancer as small as 45%. Since we did not see any excess in the cohort as a whole or in any other specific analysis by length of exposure or latency, we conclude that there is no relationship between occupational exposure to vinyl chloride and an increased risk of lymphatic and hematopoietic cancer.

R&S 040445

**MISCARRIAGES**

**AND**

**BIRTH DEFECTS**

**INFANTE ET AL 1976 STUDY**  
**MEAN PATERNAL AGE, NUMBER OF PREGNANCIES, AND FETAL**  
**DEATH-RATES ACCORDING TO HUSBAND'S V.C. EXPOSURE**

|                                           | Controls | Primary<br>VCM<br>Exposure |
|-------------------------------------------|----------|----------------------------|
| <i>Prior to husband's exposure:</i>       |          |                            |
| Number of families                        | 95       | 70                         |
| Mean paternal age at conception (yr.)     | 23.0     | 26.4                       |
| Number of fetal deaths among wives        | 11       | 15                         |
| Number of pregnancies                     | 159      | 148                        |
| Age-adjusted fetal deaths/100 pregnancies | 6.9      | 6.1                        |
| <i>Subsequent to husband's exposure:</i>  |          |                            |
| Number of families                        | 113      | 62                         |
| Mean paternal age at conception (yr.)     | 30.4     | 30.2                       |
| Number of fetal deaths among wives        | 24       | 23                         |
| Number of pregnancies                     | 273      | 139                        |
| Age-adjusted fetal deaths/100 pregnancies | 8.8      | 15.8                       |

**INFANTE ET AL 1976 STUDY**  
**MEAN PATERNAL AGE, NUMBER OF PREGNANCIES, AND FETAL**  
**DEATH-RATES ACCORDING TO HUSBAND'S V.C. EXPOSURE**  
**EXCLUDING PREGNANCIES OF WOMEN WITH >3 FETAL DEATHS**

|                                                 | Controls | Primary<br>VCM<br>Exposure |
|-------------------------------------------------|----------|----------------------------|
| <i><b>Prior to husband's exposure:</b></i>      |          |                            |
| Mean paternal age at conception (yr.)           | 23.0     | 26.3                       |
| Number of fetal deaths among wives              | 11       | 9                          |
| Number of pregnancies                           | 159      | 141                        |
| Age-adjusted fetal deaths/100 pregnancies       | 6.9      | 3.1                        |
| <i><b>Subsequent to husband's exposure:</b></i> |          |                            |
| Mean paternal age at conception (yr.)           | 30.2     | 30.8                       |
| Number of fetal deaths among wives              | 18       | 14                         |
| Number of pregnancies                           | 265      | 120                        |
| Age-adjusted fetal deaths/100 pregnancies       | 6.8      | 10.8                       |

**INFANTE ET AL 1976 STUDY  
PATERNAL AGE DISTRIBUTION FOR FETAL DEATHS  
ACCORDING TO HUSBAND'S V.C. EXPOSURE**

| Paternal age (yr)               | <u>Controls</u> |              | <u>Primary exposure</u> |              |
|---------------------------------|-----------------|--------------|-------------------------|--------------|
|                                 | Pregnancies     | Fetal deaths | Pregnancies             | Fetal deaths |
| <i>Before exposure:</i>         |                 |              |                         |              |
| <20                             | 31              | 2 (6.5%)     | 7                       | 0            |
| 20-24                           | 80              | 4 (5.0%)     | 44                      | 2 (4.5 / )   |
| 25-29                           | 38              | 4 (10.5%)    | 56                      | 7 (12.5%)    |
| 30-34                           | 6               | 1            | 27                      | 5 (18.5 / )  |
| >35                             | 4               | 0            | 14                      | 1            |
| All ages, crude rate            | 159             | 11 (6.9%)    | 148                     | 15 (10.1%)   |
| Mean paternal age at conception | 23.0 yr.        | -            | 26.4 yr.                | -            |
| Age-adjusted rate*              | -               | -            | -                       | (6.1%)       |
| <i>After exposure:</i>          |                 |              |                         |              |
| <20                             | 1               | 0            | 0                       | -            |
| 20-24                           | 43              | 4 (9.3%)     | 22                      | 3 (13.6%)    |
| 25-29                           | 87              | 3 (3.4%)     | 48                      | 11 (22.9%)   |
| 30-34                           | 87              | 7 (8.0%)     | 36                      | 3 (8.3%)     |
| >35                             | 55              | 10 (18.2%)   | 33                      | 6 (18.2 / )  |
| All ages, crude rate            | 273             | 24 (8.8%)    | 139                     | 23 (16.5%)   |
| Mean paternal age at conception | 30.4 yr.        | -            | 30.2 yr.                | -            |
| Age-adjusted rate*              | -               | (8.8%)       | -                       | (15.8%)      |

\* Fetal mortality-rates for primary V.C. exposure group are direct age adjusted to the paternal age distribution of the pregnancies in the control group.




FIG. 1. Fetal deaths according to paternal age for men exposed and not exposed to vinyl chloride monomer [adapted from Ref. (6)].

## **VCM REPRODUCTIVE TOXICOLOGY**

**Animal studies have shown that exposure to high levels of VCM during pregnancy resulted more often in high rates of fetal loss and miscarriage than in birth defects.**

## **COMMENTS REGARDING THE INFANTE ET AL (NIOSH) STUDY**

**(late) Reuel Stillones (Dean - Public Health - Univ. of Texas)**

**"The problem may be viewed in different ways, but no matter how it is viewed, that analyses is wrong, for it implies that the hazard affects the entire age span, and it intentionally dilutes the strong association in persons ages 25-29 with the zero associations in the other age groups."**

## **COMMENTS REGARDING THE INFANTE ET AL (NIOSH) STUDY**

**David Schottenfeld (Dept. Chair - Epidemiology, Univ. of Mich.)**

**"While the authors felt that these observations were likely to reflect a real difference in pregnancy outcome not attributable to either interviewer or patient recall bias, the conclusions were based on indirect sources of information and could not take into account the multiplicity of material factors known to affect pregnancy outcome. The study design precluded documenting in even the crudest manner the validity of pregnancy histories. Without such adjustments and validation, the inferences made by Infante and colleagues cannot be sustained and little light is shed on the possible association of abnormal pregnancy outcome with paternal occupational exposure to VCM."**

**THERIAULT ET AL 1983 STUDY  
BIRTH DEFECT STUDY  
SHAWINIGAN, CANADA**

**FOUR OBJECTIVES**

- 1. Document birth-defect rate previously observed**
- 2. Correlate monthly and seasonal variations of length defects with VCM in the environment**
- 3. Correlate geographic variations in birth-defect rates with estimates of VCM in the air**
- 4. Compare a group of parents who gave birth to malformed infants with a control group with respect to residential and occupational histories.**

R&S 040454




Fig. 1. Monthly distribution of birth-defect rates.

**THERIAULT ET AL 1983 STUDY  
COMPARISON OF TOTAL BIRTH DEFECTS AND CNS  
BIRTH DEFECTS BETWEEN SCHOOL DISTRICTS WITH  
HIGH AND LOW ATMOSPHERIC VINYL CHLORIDE CONCENTRATION**

|                                   | <b>School Districts<br/>With High<br/>VCM Levels</b> | <b>School Districts<br/>With Low<br/>VCM Levels</b> | <b>Total</b> |
|-----------------------------------|------------------------------------------------------|-----------------------------------------------------|--------------|
| <b>Births with defects</b>        | <b>87</b>                                            | <b>70</b>                                           | <b>157</b>   |
| <b>Births without defects</b>     | <b>2,285</b>                                         | <b>2,125</b>                                        | <b>4,410</b> |
| <b>Births with CNS defects</b>    | <b>16</b>                                            | <b>13</b>                                           | <b>29</b>    |
| <b>Births without CNS defects</b> | <b>2,356</b>                                         | <b>2,182</b>                                        | <b>4,538</b> |
| <b>Total births</b>               | <b>2,372</b>                                         | <b>2,195</b>                                        | <b>4,567</b> |

**THERIAULT ET AL 1983 STUDY  
DISTRIBUTION OF CASES AND CONTROLS BY  
DISEASES OF THE MOTHERS DURING PREGNANCY**

| <b>Mother's Occupation</b>                                     | <b>Before<br/>Pregnancy</b> | <b>During<br/>Pregnancy</b> | <b>Before<br/>Pregnancy</b> | <b>During<br/>Pregnancy</b> |
|----------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| <b>Work outside home<br/>without exposure to<br/>chemicals</b> | <b>41</b>                   | <b>22</b>                   | <b>42</b>                   | <b>20</b>                   |
| <b>Work in VCM industry</b>                                    | <b>0</b>                    | <b>0</b>                    | <b>0</b>                    | <b>0</b>                    |
| <b>Work outside home<br/>with exposure to<br/>chemicals</b>    | <b>2</b>                    | <b>1</b>                    | <b>2</b>                    | <b>1</b>                    |
| <b>Stay at home</b>                                            | <b>25</b>                   | <b>45</b>                   | <b>24</b>                   | <b>47</b>                   |
| <b>Total</b>                                                   | <b>68</b>                   | <b>68</b>                   | <b>68</b>                   | <b>68</b>                   |

**THERIAULT ET AL 1983 STUDY  
DISTRIBUTION OF CASES AND  
CONTROLS BY FATHER'S OCCUPATION**

| <b>Father's Occupation</b>                                   | <b>Cases</b> | <b>Controls</b> |
|--------------------------------------------------------------|--------------|-----------------|
| <b>Ever worked in vinyl chloride industry</b>                | <b>0</b>     | <b>0</b>        |
| <b>Ever worked in industries with exposure to chemicals</b>  | <b>20</b>    | <b>25</b>       |
| <b>Never worked in industries with exposure to chemicals</b> | <b>43</b>    | <b>39</b>       |
| <b>Unknown</b>                                               | <b>5</b>     | <b>4</b>        |
| <b>Total</b>                                                 | <b>68</b>    | <b>68</b>       |

## **THERIAULT ET AL CONCLUSION**

**"We were unable to substantiate the presence of an association between VCM in the air and birth defects in the exposed community. In view of the high numbers of angiosarcoma of the liver observed among production workers and the possible large emissions of VCM, it can mean that such an association does not exist. It can also be the result of a small number of observations. The probability of finding an excess of birth defects in the highly exposed districts twice as high as in the poorly exposed ones was 80%. The probability would have been 99% had the excess been three times as high."**

## **POLYNEUROPATHY**

**Vinyl chloride has not undergone scrutiny as a neurotoxic chemical. However, lifetime animal toxicology studies have not reported, on an incidental basis, polyneuropathy.**